Dor BioPharma and Pacific Healthcare Sign Collaborative Agreement
Dor BioPharma has entered into a collaboration with Pacific Healthcare Thailand Co, under which Pacific will act as Dor’s sponsor to administer a Named Patient Access Program for orBec to patients suffering from acute gastrointestinal graft-versus-host disease in Thailand as well as other Association of Southeast Asian Nations member countries including Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines and Vietnam.
The Named Patient Access Program (NPAP) is a compassionate use drug supply program under which medical practitioners can legally supply investigational drugs to their eligible patients.
Under this program, investigational drugs can be administered to patients who are suffering from serious illnesses until the drug is approved by the various regional regulatory authorities. Pacific and Dor will share revenues generated by sales of orBec through the NPAP. Dor will manufacture and supply orBec to Pacific, while Pacific will be responsible for all distribution costs in the territory.
Christopher Schaber, president and CEO of Dor, said: “We are very familiar with Pacific Healthcare and have great confidence in their ability to manage the NPAP in Thailand and their other territories. While we work to complete orBec’s clinical development, we are continuing our worldwide strategy of making this important therapy available to patients suffering from acute gastrointestinal graft-versus-host disease wherever possible.”